Literature DB >> 27227384

Assessment of lung deposition and analysis of the effect of fluticasone/salmeterol hydrofluoroalkane (HFA) pressurized metered dose inhaler (pMDI) in stable persistent asthma patients using functional respiratory imaging.

J De Backer1, C Van Holsbeke1, W Vos1, S Vinchurkar1, P Dorinsky2, J Rebello3, M Mangale3, B Hajian4, W De Backer4.   

Abstract

BACKGROUND: Unambiguously for inhaled products, PK measures are best suited for ensuring that the total systemic exposure is equivalent for two products but cannot provide regional information about lung deposition and structural changes. Functional respiratory imaging (FRI) has been demonstrated to be sensitive for distinguishing small but imperative differences related to a single treatment.
METHODS: In this study FRI is used in 16 asthmatic patients to assess equivalence in regional deposition for two products (fluticasone/salmeterol, test and reference) by directly measuring regional functional and structural changes within the lungs following its administration.
RESULTS: No differences were observed between the lung deposition patterns and the effects on lung structure and function of two products, having the same formulation and manufactured by different organizations using FRI.
CONCLUSIONS: Results using FRI complement PK assessments. The added value of this approach to the conventional clinical methods could be significant.

Entities:  

Keywords:  Functional respiratory imaging; asthma; fluticasone propionate; lung deposition; salmeterol

Mesh:

Substances:

Year:  2016        PMID: 27227384     DOI: 10.1080/17476348.2016.1192464

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  7 in total

1.  Reproducibility of airway luminal size in asthma measured by HRCT.

Authors:  Robert H Brown; Robert J Henderson; Elizabeth A Sugar; Janet T Holbrook; Robert A Wise
Journal:  J Appl Physiol (1985)       Date:  2017-07-13

2.  Patient-specific modeling of aerosol delivery in healthy and asthmatic adults.

Authors:  Kamran Poorbahrami; David G Mummy; Sean B Fain; Jessica M Oakes
Journal:  J Appl Physiol (1985)       Date:  2019-09-12

3.  Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.

Authors:  Cedric Van Holsbeke; Jan De Backer; Wim Vos; Jonathan Marshall
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

4.  Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity.

Authors:  J Clukers; M Lanclus; B Mignot; C Van Holsbeke; J Roseman; S Porter; E Gorina; E Kouchakji; K E Lipson; W De Backer; J De Backer
Journal:  Respir Res       Date:  2018-11-06

5.  A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD.

Authors:  Wilfried De Backer; Jan De Backer; Wim Vos; Ilse Verlinden; Cedric Van Holsbeke; Johan Clukers; Bita Hajian; Shahid Siddiqui; Martin Jenkins; Colin Reisner; Ubaldo J Martin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-08-30

Review 6.  Asthma management with breath-triggered inhalers: innovation through design.

Authors:  Mário Morais-Almeida; Helena Pité; João Cardoso; Rui Costa; Carlos Robalo Cordeiro; Eurico Silva; Ana Todo-Bom; Cláudia Vicente; José Agostinho Marques
Journal:  Asthma Res Pract       Date:  2020-06-06

7.  Functional respiratory imaging in relation to classical outcome measures in cystic fibrosis: a cross-sectional study.

Authors:  Eline Lauwers; Annemiek Snoeckx; Kris Ides; Kim Van Hoorenbeeck; Maarten Lanclus; Wilfried De Backer; Jan De Backer; Stijn Verhulst
Journal:  BMC Pulm Med       Date:  2021-08-04       Impact factor: 3.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.